Answers are grounded in this paper and cite their sources.
Case report describes disease relapse and treatment adaptation in an 82-year-old woman with monoclonal gammopathy of renal significance, highlighting the need for tailored multidisciplinary care.
We present the case of an 82-year-old woman diagnosed with monoclonal gammopathy of renal significance (MGRS) with the presence of different and peculiar kidney lesions, who began treatment with bortezomib and dexamethasone, presenting during her evolution a relapse. Although the bone marrow biopsy in this case showed plasma cells as pathologic clone and there was also a reduction after chemotherapeutic treatment, rituximab was proposed as a second line. We suspected that the relapse was possibly due to another precursor as B-cell or lymphoplasmacytic cell clone. We review the literature and suggest that the treatment for MGRS should be patient-tailored, preferably by consulting a multidisciplinary team. Future research is needed to better understand the disease course and establish the efficacy and safety of the therapeutic approach for the relapse of MGRS.
No takes yet. Share an insight, caveat, or question.
Flor et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: